Skip to main content

Table 2 HPV vaccine efficacy against genital disease in FUTURE I/II (Gardasil®) and PATRICIA (Cervarix®) trials

From: Answering human papillomavirus vaccine concerns; a matter of science and time

HPV 16/18 associated % efficacy (95% CI) Rate reduction
FutureI/II  
MITT/TVC-naive   
CIN2 100.0 (91.9-100) 0.3
CIN3 100.0 (90.5-100) 0.2
AIS 100.0 (<0-100) <0.1
VIN2/3 or VAIN2/3 95.4 (71.5-99.9) <0.1
Genital warts 96.4 (91.4-98.9) 0.8
ITT/TVC   
CIN2 54.8 (40.8-65.7) 0.3
CIN3 45.1 (29.8-57.3) 0.3
AIS 60.0 (<0-87.3) <0.1
VIN2/3 or VAIN2/3 78.5 (55.2-90.8) <0.1
Genital warts 79.5 (73.0-84.6) 0.8
PATRICIA   
MITT/TVC-naive   
CIN2+ 99.0 (94.2-100) 0.47
CIN3+ 100.0 (85.5-100) 0.13
AIS 100.0 (15.5-100) 0.03
ITT/TVC   
CIN2 60.7 (49.6-69.5) 0.43
CIN3 45.7 (22.9-62.2) 0.13
AIS 70.0 (–16.6-94.7) 0.02
  1. Abbreviations: AIS Adenocarcinoma in situ, CIN cervical interepithelial neoplasia, VIN/VaIN Vulvar/vaginal intraepithelial neoplasia, MITT modified intention to treat, ITT Intention to treat, TVC Total vaccine cohort, CI Confidence interval. Rate reduction is measured as per 100 women years. Adapted from [6].
\